Current approaches to first-line treatment of advanced colorectal cancer

Clinical Colorectal Cancer

Volumn 4, Issue SUPPL. 1, 2004, Pages

  Goldberg, Richard M ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

5 fluorouracil; FOLFOX; Irinotecan; Leucovorin; Neuropathy; Neutropenia; Oxaliplatin

Indexed keywords

BEVACIZUMAB; CISPLATIN; DOXORUBICIN; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; NEW DRUG; OXALIPLATIN; PLACEBO; PLATINUM DERIVATIVE;

ADULT; ADVANCED CANCER; ALOPECIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DRUG ACTIVITY; DRUG FATALITY; DRUG POTENTIATION; FEBRILE NEUTROPENIA; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; MONOTHERAPY; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PARESTHESIA; PERIPHERAL NEUROPATHY; PROTEINURIA; SENSORY NEUROPATHY; THROMBOCYTOPENIA; THROMBOEMBOLISM; VOMITING;

EID: 3042769441     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2004.s.002     Document Type: Article

References (31)

1. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343:905-914.
2. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluoroucacil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355:1041-1047.
3. Kohne C-H, Van Cutsem E, Wils JA, et al. Irinotecan improves the activity of the AIO regimen in metastatic colorectal cancer: results of EORTC GI Group study 40986. Proc Am Soc Clin Oncol 2003; 22:254 (Abstract #1018).
4. Raymond E, Buquet-Fagot C, Djelloul S, et al. Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate sythase inhibitor AG337 in human colon, breast and ovarian cancers. Anticancer Drugs 1997;8:876-885.
5. Machover D, Diaz-Rubio E, de Gramont A, et al. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 1996; 7:95-98.
6. Maindrault-Goebel F, de Gramont A, Louvet D, et al. Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR). Ann Oncol 2000; 11:1477-1483.
7. Andre T, Bensmaine MA, Louvet C, et al. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J Clin Oncol 1999;17: 3560-3568.
8. Maindrault-Goebel F, Louvet C, Andre T, et al. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimens as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR. Eur J Cancer 1999; 35:1338-1342.
9. Maindrault-Goebel F, de Gramont A, Louvet C, et al. High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7). Eur J Cancer 2001;37:1000-1005.
10. Martoni A, Mini E, Pinto C, et al. Oxaliplatin and protracted continuous 5-fluorouracil infusion in patients with pretreated advanced colorectal carcinoma. Ann Oncol 2001; 12:519-524.
11. Chau I, Webb A, Cunningham D, et al. Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer. Br J Cancer 2001; 85:1258-1264.
12. Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000;18:136-147.
13. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-2947.
14. Grothey A, Deschler B, Kroening H, et al. Phase III study of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (Mayo) vs weekly high-dose 24h 5-FU infusion/FA + oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACRC). Proc Am Soc Clin Oncol 2002;21:129a (Abstract #512).
15. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;21:23-30.
16. Sargent DJ, Niedzwiecki D, O'Connell MJ, et al. Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. N Engl J Med 2001;345:144-145.
17. André T, Cervantes A, Figer A, et al. OPTIMOX study: FOLFOX7 compared to FOLFOX4 in metastic colorectal cancer (CRC) - results of a randomized study. Eur J Cancer 2003; 1(Suppl 5):S94 (Abstract #306).
18. Comella P, Crucitta E, De Vita F, et al. Addition of either irinotecan or methotrexate to bolus 5-fluorouracil and high-dose folinic acid every 2 weeks in advanced colorectal carcinoma: a randomised study by the Southern Italy Cooperative Oncology Group. Ann Oncol 2002; 13:866-873.
19. Comella P, Massidda B, Filippelli G, et al. Biweekly oxaliplatin (OXA) or irinotecan (IRI) with high dose folinic acid (FA) and 5-fluorouracil (FU) i.v. bolus in advanced colorectal carcinoma (ACC): Southern Italy Cooperative Oncology Group (SICOG 0103) randomized study. Proc Am Soc Clin Oncol 2003; 22:280 (Abstract #1123).
20. Colucci G, Maiello E, Gabbia V, et al. Preliminary results of a randomized multicenter trial of the Gruppo Oncologico Italia Meridionale (GOIM) comparing FOLFIRI vs FOLFOX in advanced colorectal cancer (ACC) patient. Proc Am Soc Clin Oncol 2003; 22:255 (Abstract #1021).
21. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22:229-237.
22. Carter SK. Clinical strategy for the development of angiogenesis inhibitors. Oncologist 2000; 5(suppl 1):51-54.
23. Cherrington JM, Strawn LM, Shawver LK. New paradigms for the treatment of cancer: the role of anti-angiogenesis agents. Adv Cancer Res 2000, 79:1-38.
24. Rosen L. Antiangiogenic strategies and agents in clinical trials. Oncologist 2000; 5(suppl 1): 20-27.
25. Reinmuth N, Parikh AA, Ahmad SA, et al. Biology of angiogenesis in tumors of the gastrointestinal tract. Microsc Res Tech 2003; 601:199-207.
26. Ferrara N. Molecular and biological properties of vascular endothelial growth factors. J Mol Med 1999; 77: 527-543.
27. McMahon G, VEGF receptor signaling in tumor angiogenesis. Oncologist 2000; 5(suppl 1): 3-10.
28. Kabbinavar FF, Wong JT, Ayala RE, et al. The effect of antibody to vascular endothelial cell growth factor and cisplatin on the growth of lung tumors in nude mice. Proc Am Assoc Cancer Res 1995; 36:488 (Abstract #2906).
29. Borgstrom P, Gold DP, Hillan KJ, et al. Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin. Anticancer Res 1999; 19:4203-4214.
30. Kabbinavar F, Hurwitz HI, Fehrenbacher L. et al. Phase II randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovarin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21:60-65.
31. Hurwitz H, Fehrenbacher L, Cartwright T, et al. Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): results of a phase III trial of bevacizumab in combinations with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC. Proc Am Soc Clin Oncol 2003. Available at: www.asco.org/hurwitz∉3646. Abstract #3646.